Safety, tolerability and efficacy of the use of tixagevimab/cilgavimab as pre-exposure COVID-19 prophylaxis in kidney and simultaneous pancreas kidney transplant recipients.

Abstract

The COVID-19 pandemic resulted in high mortality rates in immunocompromised people, especially those who have received solid organ transplants. In this cohort of 540 transplant recipients who received tixagevimab/cilgavimab (Evusheld®) in Australia and New Zealand between January 2022 and January 2023, 11 (2%) Evusheld®-treated recipients experienced moderate to severe COVID-19 infection, with two deaths from COVID-19 pneumonitis. Less than 0.5% experienced adverse events from Evusheld®. Prophylactic monoclonal antibody therapy may be considered an important adjunct to vaccination among immunocompromised patients to prevent severe infection during future viral outbreaks.